# Pozelimab + cemdisiran PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pozelimab-cemdisiran

> Pozelimab + cemdisiran, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | pozelimab + cemdisiran |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Generalized Myasthenia Gravis](https://sec-api.dev/indications/generalized-myasthenia-gravis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 8, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05070858 (A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT05070858

## Same indication

- [ALXN1720](https://sec-api.dev/pdufa/alxn1720) (AZN)
- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)
- [Efgartigimod iv or efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc) (ARGX)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [Gefurulimab](https://sec-api.dev/pdufa/gefurulimab) (AZN)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [Remibrutinib (blinded)](https://sec-api.dev/pdufa/remibrutinib-blinded) (NVS)
- [APRIL (telitacicept)](https://sec-api.dev/pdufa/telitacicept) (VOR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pozelimab-cemdisiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pozelimab + cemdisiran PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pozelimab-cemdisiran

```bibtex
@misc{secapidev_pdufa_pozelimab_cemdisiran_20261116,
  title        = {Pozelimab + cemdisiran PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pozelimab-cemdisiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pozelimab_cemdisiran_20261116","title":"Pozelimab + cemdisiran PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pozelimab-cemdisiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
